PDLIM3 knockdown promotes ferroptosis in endometriosis progression via inducing Gli1 degradation and blocking Hedgehog signaling pathway.

Autor: Liu M; Gynecology Treatment Area II, Songyuan City Central Hospital, No.1188, Wenhua Road, Ningjiang District, Songyuan, 138000, Jilin, China. dcliumw@tom.com., Wang X; Gynecology Treatment Area I, Songyuan City Central Hospital, Songyuan, Jilin, China., Zhu J; Gynecology Treatment Area II, Songyuan City Central Hospital, No.1188, Wenhua Road, Ningjiang District, Songyuan, 138000, Jilin, China.
Jazyk: angličtina
Zdroj: Journal of assisted reproduction and genetics [J Assist Reprod Genet] 2024 Aug; Vol. 41 (8), pp. 2117-2128. Date of Electronic Publication: 2024 May 21.
DOI: 10.1007/s10815-024-03131-8
Abstrakt: Aims: Current evidence suggests that there is no completely effective method for endometriosis (EMS) without trauma due to diverse adverse effects. Reliable evidence illustrates that inhibiting ferroptosis is a potential strategy for EMS. We sufficiently verified that the expression of endogenous protein PDZ and LIM domain 3 (PDLIM3) was significantly increased in EMS.
Methods: PDLIM3 knockdown reduced primary ectopic endometrial stromal cells' (EESCs) viability and migration, and elevated ferroptosis signaling indicators including Fe 2+ , malondialdehyde (MDA), and reactive oxygen species (ROS) in EESCs.
Results: Mechanistic studies revealed that inhibition of PDLIM3 accelerated glioma-associated oncogene-1 (Gli1) degradation and further deactivated Hedgehog signaling. Gli1 inhibitor, GANT61, abrogated the impact of PDLIM3 deletion on EESC growth, migration, and ferroptosis. In vivo experiments suggested that PDLIM3 reduction repressed the growth of endometrial lesions. Likewise, repression of PDLIM3 promoted ferroptosis and attenuated Hedgehog signaling in endometrial lesions.
Conclusions: Collectively, silencing of PDLIM3 facilitates ferroptosis in EMS by inducing Gli1 degradation and blocking Hedgehog signaling. It may provide an alternative strategy for developing therapeutic agents of EMS in the future.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: